Healthtech VC cooled since 2021 yet remains significant. Funding centers on provider workflow tools. Bay Area leads. Exits slowed in 2023, while AI progress supports continued opportunity.
Real estate provides income and diversification as cap rates stabilize relative to bonds, sector dynamics diverge, and U.S. rental yields and data center demand highlight opportunities across risk, return, geography.
An investor primer on ESG in private markets covering materiality, integration across PE, VC, and credit, diligence and value creation levers, reporting frameworks, and regulations shaping risk, returns, and exits.
Private credit is expanding globally, it has outperformed traditional fixed income, attracts pension funds and family offices, and stays resilient despite fundraising volatility and higher rates.
IPO activity remains subdued after 2022’s freeze, with modest reopening in 2023. Tech and healthcare lead limited deals. Proceeds and counts trail prior years, and post-IPO performance has generally lagged.
U.S. private markets cooled in 2023, with VC rounds shrinking, capital concentrating in health, enterprise software, and fintech, while private credit gained traction and green tech, generative AI led growth.
Understand the FDA drug approval process with a guide to regulatory pathways, INDs, clinical trial phases, timelines, costs, success rates, and expedited programs that accelerate therapies from discovery to market.